Long-term follow-up of AL-001 eye injection for wet AMD
Part of Eyes & vision clinical trials.
This trial is a long-term follow-up for people who already received the AL-001 eye injection for wet age-related macular degeneration (wet AMD) in an earlier study. It will check how you are doing over time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have been in the earlier AL-001 study and received the AL-001 eye injection.
- You or your legal representative must agree to join this study and sign a consent form.
- You must be ready and able to follow the planned visits and procedures.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new eye injection called AL-001 for people with wet age-related macular degeneration (AMD), a condition that causes blurry vision. The injection aims to stop the growth of abnormal blood vessels in the eye and improve vision.
This trial tests a new eye injection to treat wet age-related macular degeneration (AMD), a condition that can cause blurry vision. The study checks if the injection is safe and helpful for people with active AMD.
This study checks on the long-term safety and effects of a one-time treatment (EXG102-031) for wet age-related macular degeneration. It is only for people who already received that treatment in a previous study.
This trial tests a new gene therapy, FT-003, for people with wet AMD. It aims to see if a single treatment can help stop vision loss and may reduce the need for frequent eye injections.
This trial tests a new gene therapy called RRG001 for people with the 'wet' form of age-related macular degeneration. It aims to treat leaky blood vessels in the eye that can cause vision loss, possibly reducing the need for frequent eye injections.
This trial tests a one-time gene therapy injection under the retina for people with wet age-related macular degeneration (AMD), which causes blurry vision from abnormal blood vessels. It aims to reduce the need for frequent eye injections by delivering a treatment that may help the eye produce its own medicine.
Hear when a new Wet Age-related Macular Degeneration (wAMD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.